Modi-2 / Scancell - LARVOL DELTA

Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers. (PubMed, NPJ Vaccines) - "Strong T cell responses and anti-tumour immunity in mouse tumour models was stimulated against against B16 melanoma (p = 0.0113), CT26 colorectal cancer (p < 0.0001) and 4T1 breast cancer (p = 0.0090). We demonstrate that human lung, colorectal, breast and prostate tumours express the Modi-2 target antigens and propose the Modi-2 vaccine has potential for translation into clinic in several cancer indications."

Journal • Breast Cancer • Colorectal Cancer • Melanoma • Oncology • Prostate Cancer • Solid Tumor • CD4

Scancell to present three posters at the Seventh International Cancer Immunotherapy Conference (Scancell Press Release) - "Scancell Holdings plc...announces it will present three posters at the Seventh International Cancer Immunotherapy Conference, jointly organised by the American Association for Cancer Research, the European Network for Cancer Immunotherapy and the Cancer Research Institute and taking place on 20-23 September 2023 in Milan, Italy....'Showcasing the potential of our technology platforms to generate further pipeline assets with high value partnering opportunities, we will be presenting encouraging data on both the Moditope^® and GlyMab^® platforms. Furthermore, we will be presenting data bolstering the potential of Modi-2 as a solid tumour cancer therapy and further characterising the response to Moditope^® peptides in preclinical studies."

Preclinical • Oncology • Solid Tumor

Interim Results for the 6 months ended 31 October 2022 (Scancell Press Release) - "In-licensed the SNAPvax™ technology from Vaccitech plc to formulate and manufacture Modi-2, with the aim of initiating a Phase 1 clinical study in cancer patients during H1 2024....Plans to take two GlyMab^® monoclonal antibodies (mAbs), a redirecting T-cell bispecific (TCB) antibody and a T cell costimulatory mAb into the clinic, with initiation of TCB manufacturing in H1 2023 prior to clinical evaluation in 2024."

New P1 trial • New trial • Oncology